Navigation Links
Landauer, Inc. Reports Fiscal 2011 Second Quarter Results
Date:5/3/2011

ously reported change in the supply relationship between Landauer and Nagase Landauer, which converted its customer base from Luxel to the InLight technology during fiscal 2010.  Nagase Landauer no longer purchases service badges from the Company.  The historical Luxel badge revenues were partially replaced by a royalty arrangement, resulting in no corresponding impact on net income.  Without the Nagase Landauer impact, domestic Radiation Monitoring revenues declined 6 percent, or $1.2 million, driven by lower non-recurring InLight equipment sales, primarily to the Canadian government agency responsible for occupational monitoring and radiation emergency preparedness for the citizens of Canada.  International Radiation Monitoring revenues increased 14 percent, or $1.0 million, on organic growth in most regions and the strengthening of most foreign currencies against the dollar.

Radiation Monitoring gross margin for the second fiscal quarter of 2011 increased to 71 percent from 68 percent in the year ago period, primarily due to the decline in lower margin sales to Nagase Landauer.  Selling, general and administrative costs for the second fiscal quarter of 2011 increased 3 percent, or $0.2 million, to $7.4 million.  The increase is due primarily to the strengthening of most foreign currencies against the dollar.  Operating income, inclusive of the impact of acquisition related transaction and reorganization costs, for the second fiscal quarter of 2011 increased 2 percent, or $0.2 million, to $12.1 million compared with operating income of $11.9 million for fiscal 2010.

Medical Physics SegmentMedical Physics revenues for the second fiscal quarter of 2011 increased 40 percent, or $1.4 million, to $4.8 million on $0.7 million of organic growth and $0.7 million due to the impact of acquired companies.  The gross margin increased to 23 percent from 22 percent in the year ago period.  Selling, general and
'/>"/>

SOURCE Landauer, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Landauer, Inc. Appoints Two New Members to Board of Directors
2. Cynosure Reports Financial Results for the First Quarter of 2011
3. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
4. VIVUS Reports First Quarter 2011 Financial Results
5. Dendreon Reports First Quarter 2011 Financial Results
6. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
7. Nektar Therapeutics Reports First Quarter 2011 Financial Results
8. Veteran Wall Street Securities Analyst Reports on Health Discovery Corporation
9. China Green Material Technologies, Inc. Reports 2010 Financial Results
10. GeneLink Reports Denial of Appeal
11. GeneLink Reports 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Wheaton, Illinois (PRWEB) May 04, 2015 ... treatment options for patients with arm and hand ... rehabilitation exoskeleton at its Oakbrook Terrace network site. ... foundation, the Armeo®Spring is a highly-regarded treatment option ... In acquiring the Armeo®Spring, Marianjoy becomes one of ...
(Date:5/1/2015)... OncoTAb, Inc., a University ... announced that Pinku Mukherjee, Ph.D. has received the ... Governors’ highest faculty honor. Mukherjee received the award, which ... her innovative research and development of cancer diagnostics and ... crowning moment in my scientific career,” said Mukherjee, OncoTAb ...
(Date:5/1/2015)... DIEGO , May 1, 2015 ... company engaged in the development of biosimilar therapeutics ... announced today that its first quarter 2015 financial ... 2015, before the open of market. At 8:30 am ... call to discuss the financial results and provide ...
(Date:5/1/2015)... -- A new report by  visiongain  forecasts ... $22.4bn in 2019. That revenue forecast and others appear ... 2015-2025 ,  published in March 2015. ... forecasts and qualitative analyses of the antithrombotic drugs market. ... London, UK . It produces analyses ...
Breaking Biology Technology:Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced ... approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme ... patients refractory to conventional therapy.  Chronic gout that is ... failed to normalize serum uric acid and whose signs ...
... Calif., Sept. 14 The launch of IntriMed ... Innovation Center in Oxnard, Calif. were announced today ... design and manufacture of ultra-precise components for the ... 23 year heritage of engineering innovation, IntriMed ( ...
... (Nasdaq: BSTC ), a biopharmaceutical company developing ... President, Tom Wegman, will present at the upcoming UBS ... at 7:30am ET at the Grand Hyatt New York ... of the presentation can be accessed under "Calendar of ...
Cached Biology Technology:FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 2FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 3FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 4FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 5FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 6FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 7FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 8IntriMed Technologies Launched to Address Challenges Faced by Medical Device Manufacturers 2IntriMed Technologies Launched to Address Challenges Faced by Medical Device Manufacturers 3
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... why premature birth is a growing problem in the United ... that pre-pregnancy depressive mood appears to be a risk factor ... however, have nearly two times the odds of having a ... a University of Washington assistant professor of social work and ...
... pregnant women hinders brain development in their children ... thyroid hormone levels in the fetal brain, a ... Wednesday at The Endocrine Society,s 91st Annual Meeting ... moderate drinking during pregnancycan cause neurodevelopmental disorders, such ...
... , This release is available in ... this is particularly true for cancer medicine. The ... further increased if research results are swiftly transferred from ... research transfer, also called translational research, will now be ...
Cached Biology News:Pre-pregnancy depressed mood may heighten risk for premature birth 2Pre-pregnancy depressed mood may heighten risk for premature birth 3Specific genetic cause of fetal alcohol-related developmental disorders found 2German Research Minister Schavan: 'Rapid knowledge transfer can safe lives' 2German Research Minister Schavan: 'Rapid knowledge transfer can safe lives' 3
Human ABCG2 MAb (Clone 5D3)...
... The Beacon 2000 One-Step FP ... characteristic high and low fluorescence polarization ... users of the Beacon 2000 System. ... the polarization values generated by their ...
...
... vitro cell labeling mix, 92.5 ... solution stabilized with 0.1% 2-mercaptoethanol ... 3,4-dicarboxylic acid. *Amino acid mixture ... containing l-[35S]Methionine and l-[35S]Cysteine. * ...
Biology Products: